MS and Driving
Driving with MS isn’t just about getting from point A to point B — it’s like adding a few extra…
Categories
Latest Blog Posts
- Ocrevus in Advanced Progressive Multiple Sclerosis (pertaining to younger and elder patients with MS)
- The Demon Within, Surviving MS – Podcast Episode 12
- Former Indiana QB Fernando Mendoza donates $500K to University of Miami MS research initiative
- Major Breakthrough: FDA APPROVES OCREVUS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER
- Having 2nd autoimmune disease does not speed up MS progression: Study
- MS, Motherhood, and Mental Health
- Multiple Sclerosis in Children
- Men’s online MS Group asking other Men with MS to Join the Conversation
- Enough on estrogen. Let’s Learn more of Low T, and the Facts for the Men
- Brain sugar levels act as signal for myelin growth, study finds
- MS and sleep: Tips for getting better rest
- What People SHOULD Say to Someone Living with Multiple Sclerosis
- New walking station brings gait therapy right into MS patients’ homes
- Brain inflammation may help repair myelin, animal study shows
- People Wait an Average of 50 Days to See a Neurologist, and People with MS Wait Even Longer: What Can We Do to Improve Access to MS Care?
- Key Findings on GLP-1 Use in MS
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
- Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
- This Blood Test Tracks MS Activity? (Octave Explained)
- Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
